atopic dermatitis

Nektar Therapeutics presented Phase 2b REZOLVE-AD data at ACAAI 2025, highlighting rezpegaldesleukin’s potential in atopic dermatitis and comorbid asthma. The study showed statistically significant reductions in Asthma Control Questionnaire (ACQ-5) scores in patients with both conditions. Notably, patients with poorly controlled asthma experienced even greater improvements. These findings suggest that rezpegaldesleukin, an IL-2 pathway agonist, may offer benefits beyond skin symptoms by promoting regulatory T-cell activity. Phase 3 trials are planned.

Organon presented data at ACAAI 2025 showing VTAMA cream’s efficacy in children (2-17) with atopic dermatitis (AD). A sub-analysis of Phase 3 trials (ADORING 1 & 2) revealed early and clinically meaningful improvements in skin clearance (vIGA-AD, EASI-75), patient-reported outcomes (POEM), and itch (PP-NRS) at week 8, regardless of comorbidities like asthma or allergies. This largest pediatric VTAMA data set supports its use as a treatment option, demonstrating a favorable safety and efficacy profile.

Incyte’s Phase 3b TRuE-AD4 trial results, presented at ISAD, demonstrate Opzelura’s effectiveness and safety in adult patients with moderate atopic dermatitis (AD) who had inadequate responses to topical corticosteroids or calcineurin inhibitors. Opzelura significantly improved AD clinical signs, with 70% achieving EASI75 and 61.3% achieving IGA-TS at Week 8. Patients experienced rapid itch reduction and improved quality of life. Incyte plans to file for EU approval based on these data, aiming to provide a non-steroidal alternative for AD treatment.

Regeneron and Sanofi announced positive Phase 4 trial results for Dupixent in treating moderate-to-severe atopic dermatitis in adults and adolescents with skin of color. The DISCOVER trial, involving 120 patients, showed significant improvements in disease severity, itch reduction, and post-inflammatory hyperpigmentation. The safety profile aligned with previous findings. This marks a significant advancement in treating this often-underserved population.